Univercells has evolved its organizational structure and business model to optimally tackle challenges across the health value chain
Univercells affiliate timelineCorporate Governance
Board Members
Bio
Doug Neugold
Bio
Hugues Bultot
Bio
José Castillo
Bio
Pierre Morgon
Bio
Glenn Rockman
Bio
Céline Vaessen
Bio
Andrin Oswald
Bio
Timothy E. Morris
Observers
Bio
Olivier de Duve
Bio
Jean Marc Legrand
Bio
Andre Ostachkov
Bio
Rodolphe de Spoelberch
Bio
Gil Yeong Mok
Bio
Kerstin Laudemann
Bio
Alain Huriez
Bio
Nicolas Sneyers
Bio
Christina Franssen
Bio
Frank Maldonado
Bio
Hugues Bultot
Bio
Vincent Vanderborght
Bio
David Louvet
Bio
Kate Antrobus
Audit Committee
Chairman
- Timothy E. Morris
Secretary
- Vincent Vanderborght
Core
- Doug Neugold
- Hugues Bultot
Remuneration Committee
Chairman
- Doug Neugold
Secretary
- David Louvet
Core
- Glenn Rockman
- Robbie Woodman
- Christina Franssen
Sustainability Committee
Chairman
- Olivier de Duve
Secretary
- Kate Antrobus
Core
- Frank Mestdagh
- Kabeer Aziz
- Sybile van den Hove
- Christel Dewitte
- Hugues Bultot
Strategic Committee
Chairman
- Bruno van Lierde
Secretary
- Vincent Vanderborght
- David Louvet
Core
- Glenn Rockman
- Doug Neugold
- Pierre Morgon
- Hugues Bultot
- Jose Castillo
- Andrin Oswald
- Céline Vaessen
biomanufacturing infrastructure
2020
To support the industrialization and scale of our equipment portfolio, we created a dedicated company, Univercells Technologies, funded by KKR
Q1 2021
This sparked the evolution of other business units into separate affiliates – falling under the Univercells’ Group structure with accountability resting at affiliate level and the respective CEO’s
Q3 2021
After market feedback and a recognition of the value proposition of our engineering skills for new areas of biologics, Univercells Vaccines became Quantoom Biosciences
Q4 2021
Q1 2022
To further complement Univercells’ offering, RLM Consulting has been acquired to provide regulatory affairs support during the medicinal product development
2020
To support the industrialization and scale of our equipment portfolio, we created a dedicated company, Univercells Technologies, funded by KKR
Q1 2021
This sparked the evolution of other business units into separate affiliates – falling under the Univercells’ Group structure with accountability resting at affiliate level and the respective CEO’s
Q3 2021
Q4 2021
After market feedback and a recognition of the value proposition of our engineering skills for new areas of biologics, Univercells Vaccines became Quantoom Biosciences
Q1 2022
To further complement Univercells’ offering, RLM Consulting has been acquired to provide regulatory affairs support during the medicinal product development
Biologics overtaking small molecules:
Biologics vs. Small Molecules Sales (%, total $ Bn)
Small molecules
Biologics
Resulting in booming development pipelines and new manufacturing needs
Viral vector manufacturing (vaccines & gene therapy)
Development pipeline
(# therapies)
mRNA/saRNA
Development pipeline
(# therapies)
Biotech Funding increased by 7,5x Over 10 year period from $14Bn to $103Bn
Booming market and strong investor interest as a basis for future successes
IR Team Contacts
- Florent de Liedekerke
- Investment Manager
- investors@univercells.com
- +32 (0)2 790 43 90
